See more : U.S. National Telecom, Inc. (USNL) Income Statement Analysis – Financial Results
Complete financial analysis of Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- SHINTO Holdings, Inc. (2776.T) Income Statement Analysis – Financial Results
- Guangdong Kingstrong Technology Co., Ltd. (300629.SZ) Income Statement Analysis – Financial Results
- Warehouse REIT plc (WHR.L) Income Statement Analysis – Financial Results
- Ipsen S.A. (IPSEY) Income Statement Analysis – Financial Results
- Sumou Real Estate Company (9511.SR) Income Statement Analysis – Financial Results
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (603392.SS)
About Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. researches, develops, produces, distributes, and sells infectious disease diagnostic reagents and vaccines in China and internationally. The company provides COVID 19, HIV and HTLV, Hepatitis, EV-71, and Tuberculosis diagnostics test kits; Hepatitis C and Syphilis detection reagents; automated immunoassays; ELISA kits and rapid tests for infectious disease diagnostics; chemiluminescence and clinical chemistry reagents; immunodiagnostic reagents; and Hepatitis E and human papillomavirus vaccines. It serves blood banks, hospitals and clinics, reference laboratories, border inspection centers, blood-processing companies, and research institutes. The company was founded in 1991 and is headquartered in Beijing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.48B | 11.19B | 5.75B | 2.35B | 1.18B | 982.69M | 949.52M | 844.08M | 680.71M | 596.23M | 499.06M |
| Cost of Revenue | 978.70M | 1.17B | 817.71M | 442.14M | 330.86M | 269.08M | 281.19M | 230.18M | 174.75M | 142.03M | 116.66M |
| Gross Profit | 4.50B | 10.01B | 4.93B | 1.91B | 852.89M | 713.60M | 668.33M | 613.91M | 505.96M | 454.21M | 382.40M |
| Gross Profit Ratio | 82.13% | 89.54% | 85.78% | 81.22% | 72.05% | 72.62% | 70.39% | 72.73% | 74.33% | 76.18% | 76.62% |
| Research & Development | 1.20B | 1.10B | 681.82M | 314.33M | 165.98M | 138.34M | 158.82M | 130.10M | 109.47M | 97.37M | 76.01M |
| General & Administrative | 102.01M | 42.58M | 37.52M | 23.94M | 23.48M | 27.84M | 26.15M | 96.68M | 77.44M | 152.63M | 118.42M |
| Selling & Marketing | 1.52B | 3.25B | 1.69B | 690.94M | 333.39M | 265.74M | 266.08M | 251.99M | 191.16M | 171.25M | 151.07M |
| SG&A | 1.94B | 3.30B | 1.73B | 714.88M | 356.88M | 293.59M | 292.23M | 348.67M | 268.61M | 323.88M | 269.48M |
| Other Expenses | -27.09M | 19.64M | 86.42M | 57.17M | 108.74M | 1.16M | -192.69K | 21.32M | 9.36M | 19.11M | 7.00M |
| Operating Expenses | 3.14B | 4.42B | 2.50B | 1.09B | 631.60M | 541.71M | 478.05M | 483.55M | 381.16M | 326.99M | 272.75M |
| Cost & Expenses | 4.11B | 5.59B | 3.31B | 1.53B | 962.46M | 810.79M | 759.24M | 713.73M | 555.92M | 469.02M | 389.41M |
| Interest Income | 87.98M | 42.15M | 9.77M | 4.98M | 8.57M | 6.26M | 3.69M | 5.46M | 7.10M | 0.00 | 0.00 |
| Interest Expense | 6.86M | 7.67M | 5.69M | 1.69M | 1.04M | 6.04M | 4.84M | 0.00 | 1.17M | 0.00 | 0.00 |
| Depreciation & Amortization | 255.61M | 158.53M | 110.31M | 86.54M | 82.31M | 62.92M | 35.58M | 26.40M | 16.33M | 17.09M | 22.11M |
| EBITDA | 1.66B | 5.74B | 2.44B | 850.61M | 293.54M | 357.44M | 214.79M | 152.26M | 132.28M | 132.33M | 109.65M |
| EBITDA Ratio | 30.25% | 52.21% | 44.31% | 38.31% | 27.25% | 25.75% | 25.15% | 15.99% | 20.30% | 22.19% | 23.71% |
| Operating Income | 1.40B | 5.60B | 2.33B | 775.20M | 218.33M | 289.12M | 178.74M | 131.44M | 121.84M | 115.24M | 96.23M |
| Operating Income Ratio | 25.59% | 50.03% | 40.49% | 32.93% | 18.44% | 29.42% | 18.82% | 15.57% | 17.90% | 19.33% | 19.28% |
| Total Other Income/Expenses | -8.06M | -13.35M | -4.31M | -10.75M | -1.52M | 1.16M | -192.69K | 21.27M | 9.27M | 19.05M | 6.97M |
| Income Before Tax | 1.39B | 5.58B | 2.32B | 764.45M | 216.81M | 290.29M | 178.55M | 152.71M | 131.11M | 134.29M | 103.20M |
| Income Before Tax Ratio | 25.44% | 49.91% | 40.42% | 32.47% | 18.32% | 29.54% | 18.80% | 18.09% | 19.26% | 22.52% | 20.68% |
| Income Tax Expense | 146.89M | 719.39M | 244.93M | 82.64M | 6.51M | -2.59M | 28.19M | 21.23M | 24.62M | 15.83M | 23.34M |
| Net Income | 1.25B | 4.74B | 2.02B | 677.00M | 208.86M | 293.07M | 150.41M | 148.19M | 119.36M | 118.46M | 79.83M |
| Net Income Ratio | 22.78% | 42.34% | 35.15% | 28.76% | 17.64% | 29.82% | 15.84% | 17.56% | 17.53% | 19.87% | 16.00% |
| EPS | 0.99 | 3.79 | 1.64 | 0.55 | 0.17 | 0.27 | 0.15 | 0.14 | 0.12 | 0.12 | 0.08 |
| EPS Diluted | 0.99 | 3.79 | 1.64 | 0.55 | 0.17 | 0.27 | 0.15 | 0.14 | 0.12 | 0.12 | 0.08 |
| Weighted Avg Shares Out | 1.26B | 1.25B | 1.23B | 1.23B | 1.23B | 1.07B | 1.02B | 1.03B | 1.03B | 1.02B | 986.37M |
| Weighted Avg Shares Out (Dil) | 1.26B | 1.25B | 1.23B | 1.23B | 1.23B | 1.07B | 1.02B | 1.03B | 1.03B | 1.02B | 986.37M |
Source: https://incomestatements.info
Category: Stock Reports